Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)
In a large European patient cohort, leuprorelin-based ADT demonstrated an acceptable safety profile, with a low incidence of CV events.
Authors
- Stephan Mühlich
- Peter J. Goebell
- Kerstin Dienes
- E. Bismarck
- Bernd J. Schmitz‐Dräger (ORCID: https://orcid.org/0000-0002-4004-1857)
- Bertram Ottillinger (ORCID: https://orcid.org/0000-0002-7901-6165)
- Thomas Ebert (ORCID: https://orcid.org/0000-0003-1683-9276)
- Roland Starlinger
- Jutta K Bergler-Klein (ORCID: https://orcid.org/0000-0003-2591-1380)
- Oliver W. Hakenberg (ORCID: https://orcid.org/0000-0003-3684-4179)
- Natalya Benderska-Södera
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Hexal (Germany) (DE)
- Agaplesion Bethesda Krankenhaus (DE)
- University of Rostock (DE)
- Medical University of Vienna (AT)
- University of Bamberg (DE)
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1159/000543985
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Hexal AG
- Eisai
- Astellas Pharma
- Ipsen